Subretinal implant for retinitis pigmentosa
According to Dr. Eberhart Zrenner, MD, of the University of Tübingen in Germany, electronic subretinal implants provide hope for the restoration of some useful, functional vision in patients blinded by retinitis pigmentosa.
Dr. Zrenner discussed the 12-month visual and safety outcomes of a multi-center study of 1500-pixel subretinal implants at the 14th EURETINA Congress. These generate an 11x11 degree visual field to patients by stimulating the overlying bipolar cells.
The patients, whose average age was 53 years, had, on average, lost the ability to read 17 years ago. Of interest, detection, localization and recognition of shapes and objects in an ADL task was significantly better with implant power switched on than off during the first three months (p<0.05). Four patients (14%) could read letters 4-8 cm in size. Thirteen patients (45%) reported useful visual experiences, including recognition of shapes or details in daily life and 8 patients (28%) could localize objects in daily life.
Latest Articles
Making Female Leadership More than a Moment
A remarkable global confluence of women in key positions.
ESCRS Talks Technology at AAO
Europe adopts technological advances, US still waiting for lenses and lasers.
Sorting Out Simultaneous Vision IOLs
The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.
Big Advantages to Small-Aperture IOLs
Small-aperture IOLs offer superior image quality with increased range of focus.
Prioritising Self-Care
Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.
Valuing Clinical Trial Design
How inclusivity and diversity can enhance scientific accuracy in research.
Knowing Iris Repair: Using Iridodiathermy in Iris Surgery
Prepare for decentred pupils and uneven irides in multiple situations.
Neuroprotectant Treatment for MacTel Type 2
Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.